Instrument Inactif

Autres langues Orchard Therapeutics plc

Actions

ORTX

US68570P2002

Produits pharmaceutiques

Autres langues

30/04	Orchard Therapeutics Awarded Innovation Passport Designation for Otl-201 in Mps-Iiia
07/07/25	Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of Otl-203 for Mps-I Hurler Syndrome
13/05/25	Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-Term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025
12/02/25	Orchard Therapeutics Announces the Appointment of Robin Kenselaar as Chief Commercial Officer
07/05/24	Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
06/05/24	Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
03/05/24	Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
03/04/24	FDA Approves First Gene Therapy To Treat Children With Metachromatic Leukodystrophy
20/03/24	FDA approves innovative gene therapy for MLD
20/03/24	Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
18/03/24	Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
18/03/24	Orchard Therapeutics Receives FDA Approval of Lenmeldy? (atidarsagene autotemcel)
05/02/24	Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
05/02/24	Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
02/02/24	Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
26/01/24	Kyowa Kirin Co., Ltd - Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc
26/01/24	Japanese Shares Skid as Inflation Slows Faster-than-Expected in January
26/01/24	Kyowa Kirin Acquires All Outstanding Shares of Orchard Therapeutics
25/01/24	Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
24/01/24	Orchard Therapeutics plc Announces Board Changes
24/01/24	Orchard Therapeutics Completes Sale to Japan's Kyowa Kirin
24/01/24	Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
24/01/24	Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index
24/01/24	Kyowa Kirin Co., Ltd. completed the acquisition of Orchard Therapeutics plc from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.
11/12/23	Orchard Therapeutics’ Gene Therapy Gets Swiss Regulatory Approval